BioSenic S.A. (EBR:BIOS)
Belgium · Delayed Price · Currency is EUR 0.0020
0.00 (0.00%)
May 26, 2026, 10:35 AM CET
BioSenic Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 67.08 | 0.34 | 0.12 | 1.85 | 0.76 |
Cash & Short-Term Investments | 67.08 | 0.34 | 0.12 | 1.85 | 0.76 |
Cash Growth | 19441.47% | 193.39% | -93.66% | 143.22% | -94.82% |
Accounts Receivable | 9.35 | 1.01 | 1.32 | 2.49 | 0.36 |
Other Receivables | 676.58 | 0.72 | - | - | - |
Total Trade Receivables | 685.93 | 1.73 | 1.32 | 2.49 | 0.36 |
Other Current Assets | 13.34 | 0.24 | 0.41 | 0.29 | 0 |
Total Current Assets | 2,919 | 2.32 | 1.85 | 4.63 | 1.12 |
Net Property, Plant & Equipment | 5.2 | 0.01 | 0.7 | 1.42 | 0.01 |
Other Intangible Assets | 338.64 | 0.67 | 2.99 | 17.29 | - |
Goodwill | - | - | 0 | 1.8 | 0 |
Long-Term Investments | 139.25 | 0.14 | 0.01 | 0.01 | 0.03 |
Other Long-Term Assets | 2,154 | 0 | 4.01 | 4.17 | 0 |
Total Assets | 3,399 | 5.48 | 9.56 | 29.32 | 1.16 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1,122 | 2.91 | 3.87 | 2.24 | 0.21 |
Accrued Expenses | - | 0.05 | - | - | - |
Short-Term Debt | - | - | 11.82 | 8.01 | 1.25 |
Current Portion of Long-Term Debt | 2,787 | 3.65 | - | - | - |
Other Current Liabilities | 124.64 | 1.71 | 0.15 | 0.1 | 0.03 |
Total Current Liabilities | 4,033 | 7.08 | 15.84 | 10.35 | 1.49 |
Long-Term Debt | 0 | 17.8 | 16.34 | 15.78 | 2.27 |
Other Long-Term Liabilities | 27.52 | 2.98 | 0.08 | 0.07 | 0.07 |
Total Long-Term Liabilities | 27.52 | 21.06 | 16.42 | 15.85 | 2.34 |
Total Liabilities | 4,061 | 28.13 | 32.26 | 26.2 | 3.38 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 38,401 | 37.4 | 6.28 | 4.77 | 0.66 |
Additional Paid-in Capital | 15,799 | 15.8 | 5.72 | 4.52 | 3.97 |
Accumulated Other Comprehensive Income | - | - | -0.02 | -0.04 | -0.08 |
Retained Earnings | -54,861 | -77.09 | -34.89 | -5.72 | -7.22 |
Total Common Shareholders' Equity | -661.42 | -23.89 | -22.91 | 3.53 | -2.67 |
Minority Interest | - | - | 0.21 | -0.4 | - |
Shareholders' Equity | -661.42 | -23.89 | -22.71 | 3.12 | -2.67 |
Total Liabilities & Equity | 3,399 | 5.48 | 9.56 | 29.32 | 1.16 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2,787 | 21.45 | 28.16 | 23.79 | 3.53 |
Net Cash (Debt) | -2,719 | -21.1 | -28.04 | -21.95 | -2.77 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -4.17 | -0.07 | -0.20 | -0.18 | -0.13 |
Book Value | -661.42 | -23.89 | -22.91 | 3.53 | -2.67 |
Book Value Per Share | -1.01 | -0.07 | -0.17 | 0.03 | -0.13 |
Tangible Book Value | -1,000 | -24.56 | -25.9 | -15.57 | -2.67 |
Tangible Book Value Per Share | -1.53 | -0.08 | -0.19 | -0.13 | -0.13 |